Point of Care Molecular Diagnostics Market Report by Product and Service (Assays and Kits, Instruments and Analyzers, Software and Services), Technology (Polymerase Chain Reaction (PCR), Hybridization, DNA sequencing, Microarray, Isothermal Nucleic Acid Amplification Technology (INAAT), and Others), Application (Infectious Diseases, Oncology, Hematology, Prenatal Testing, Endocrinology, and Others), End User (Physicians’ Offices, Hospitals and ICUs, Research Institutes, and Others), and Region 2025-2033

Point of Care Molecular Diagnostics Market Report by Product and Service (Assays and Kits, Instruments and Analyzers, Software and Services), Technology (Polymerase Chain Reaction (PCR), Hybridization, DNA sequencing, Microarray, Isothermal Nucleic Acid Amplification Technology (INAAT), and Others), Application (Infectious Diseases, Oncology, Hematology, Prenatal Testing, Endocrinology, and Others), End User (Physicians’ Offices, Hospitals and ICUs, Research Institutes, and Others), and Region 2025-2033

Report Format: PDF+Excel | Report ID: SR112025A6271

Market Overview:

The global point of care molecular diagnostics market size reached USD 4.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 8.7 Billion by 2033, exhibiting a growth rate (CAGR) of 8.78% during 2025-2033. The increasing incidence of infectious diseases paired with rapid development in healthcare facilities is significantly driving the market growth.

Report Attribute 
Key Statistics
Base Year
2024
Forecast Years
2025-2033
Historical Years
2019-2024
Market Size in 2024
USD 4.0 Billion
Market Forecast in 2033
USD 8.7 Billion
Market Growth Rate 2025-2033 8.78%


Point-of-care (POC) molecular diagnostics refer to tests performed by physicians to diagnose and detect infectious diseases. It includes hematology, pregnancy, fertility, infectious diseases, urinalysis testing kits, and cardiometabolic and glucose monitoring devices. POC molecular diagnostics is widely used for identifying infectious agents, minimal residual disease, and gastrointestinal disorders, monitoring hemoglobin and fecal occult blood, and determining a patient's ability to metabolize a drug or drug class. These tests offer faster results, reduce complications associated with mistreatment, and improve infection control measures. As a result, POC molecular diagnostics finds extensive applications in hospitals, intensive care units (ICUs), research institutes, clinics, decentralized laboratories, and homecare facilities.

Point of Care Molecular Diagnostics Market

Point of Care Molecular Diagnostics Market Trends:

Increased Focus on Infectious Disease Diagnostics

The increasing prevalence of infectious diseases across the globe is creating a positive outlook for the market. The COVID-19 pandemic highlighted the importance of rapid testing for public health surveillance and outbreak management. POC molecular diagnostic test is a cost-effective solution widely used to manage infectious diseases, such as flu, tuberculosis, human immunodeficiency virus (HIV) infection, chlamydia, and hepatitis. It effectively supports in the early detection and containment of emerging infectious diseases, preventing their spread.

Product Enhancements

The adoption of miniaturization, nanotechnology, and microfluidics to develop low-cost, user-friendly, and highly sensitive molecular diagnostic tests is providing an impetus to the market growth. Moreover, the implementation of various government initiatives toward improving healthcare infrastructure and enhancing molecular diagnostic capabilities is positively influencing the market growth. Other factors, including rapid advancements in deoxyribonucleic acid (DNA) sequencing, rising awareness regarding advanced therapeutic and diagnostic tests, increasing geriatric population, and recent developments in cloud-connected POC diagnostic technologies, are anticipated to drive market growth.

Integration of Digital Technologies

Connecting point-of-care devices to the Internet of Things (IoT) enables real-time data collection, remote monitoring, and enhanced data management. Further, the integration of artificial intelligence technology to analyze test results, assist in diagnosis, and provide personalized treatment recommendations is creating new growth opportunities for the key market participants. In addition, the adoption of cloud-based platforms for facilitating data storage, sharing, and analysis, enabling collaboration between healthcare providers and researchers, is transforming the point of care molecular diagnostics market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global point of care molecular diagnostics market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on product and service, technology, application and end user.

Breakup by Product and Service:

Point of Care Molecular Diagnostics Market By Product and Service

  • Assays and Kits
  • Instruments and Analyzers
  • Software and Services
     

Breakup by Technology:

  • Polymerase Chain Reaction (PCR)
  • Hybridization
  • DNA sequencing
  • Microarray
  • Isothermal Nucleic Acid Amplification Technology (INAAT)
  • Others
     

Breakup by Application:

  • Infectious Diseases
  • Oncology
  • Hematology
  • Prenatal Testing
  • Endocrinology
  • Others
     

Breakup by End User:

  • Physicians’ Offices
  • Hospitals and ICUs
  • Research Institutes
  • Others
     

Breakup by Region:

Point of Care Molecular Diagnostics Market By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa


Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global point of care molecular diagnostics market. Detailed profiles of all major companies have also been provided. Some of the companies covered include:

  • Abbott Laboratories
  • Becton Dickinson and Company
  • Binx Health Inc.
  • Co-Diagnostics Inc.
  • F. Hoffmann-La Roche Ltd
  • Gene STAT Molecular Diagnostics LLC
  • Hemocue AB (Danaher Corporation)
  • Meridian Bioscience Inc.
  • Molbio Diagnostics Private Limited
  • Quidel Corporation
  • Siemens Healthcare GmbH (Siemens AG)
  • Thermo Fisher Scientific Inc.
  • Visby Medical Inc.
     

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Point of Care Molecular Diagnostics Market Recent Developments:

  • July 2024: Roche announced the acquisition of LumiraDx’s Point of Care technology for expanding access to diagnostic tests in primary care.
  • July 2024: Co-Diagnostics, Inc. announced that it will be hosting and presenting at the Association for Diagnostics & Laboratory Medicine (ADLM) annual meeting and expo in August 2024. It planned to exhibit the role of its new point-of-care and at-home Co-Dx PCR platform in limiting the global diagnostics gap for a diverse range of potential indications, including tuberculosis.

Report Scope:

Report Features Details
Base Year of the Analysis 2024
Historical Period 2019-2024
Forecast Period 2025-2033
Units Billion USD
Segment Coverage Product and Service, Technology, Application, End User, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Abbott Laboratories, Becton Dickinson and Company, Binx Health Inc., Co-Diagnostics Inc., F. Hoffmann-La Roche Ltd, Gene STAT Molecular Diagnostics LLC, Hemocue AB (Danaher Corporation), Meridian Bioscience Inc., Molbio Diagnostics Private Limited, Quidel Corporation, Siemens Healthcare GmbH (Siemens AG), Thermo Fisher Scientific Inc., Visby Medical Inc.
Customization Scope 10% Free Customization
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Key Questions Answered in This Report

The global point of care molecular diagnostics market was valued at USD 4.0 Billion in 2024.

We expect the global point of care molecular diagnostics market to exhibit a CAGR of 8.78% during 2025-2033.

The escalating demand for point of care molecular diagnostics tests across hospitals, research institutes, clinics, etc., as they offer faster results and reduce complications associated with mistreatment, is primarily driving the global point of care molecular diagnostics market.

The sudden outbreak of the COVID-19 pandemic has led to the growing adoption of point of care molecular diagnostics tests to effectively manage and control the spread of the coronavirus infection.

Based on the product and service, the global point of care molecular diagnostics market can be segmented into assays and kits, instruments and analyzers, and software and services. Currently, assays and kits hold the majority of the total market share.

Based on the technology, the global point of care molecular diagnostics market has been divided into Polymerase Chain Reaction (PCR), hybridization, DNA sequencing, microarray, Isothermal Nucleic Acid Amplification Technology (INAAT), and others. Among these, Polymerase Chain Reaction (PCR) currently exhibits a clear dominance in the market.

Based on the application, the global point of care molecular diagnostics market can be categorized into infectious diseases, oncology, hematology, prenatal testing, endocrinology, and others. Currently, infectious diseases account for the largest market share.

On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.

Some of the major players in the global point of care molecular diagnostics market include Abbott Laboratories, Becton Dickinson and Company, Binx Health Inc., Co-Diagnostics Inc., F. Hoffmann-La Roche Ltd, Gene STAT Molecular Diagnostics LLC, Hemocue AB (Danaher Corporation), Meridian Bioscience Inc., Molbio Diagnostics Private Limited, Quidel Corporation, Siemens Healthcare GmbH (Siemens AG), Thermo Fisher Scientific Inc., and Visby Medical Inc.

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Point of Care Molecular Diagnostics Market Report by Product and Service (Assays and Kits, Instruments and Analyzers, Software and Services), Technology (Polymerase Chain Reaction (PCR), Hybridization, DNA sequencing, Microarray, Isothermal Nucleic Acid Amplification Technology (INAAT), and Others), Application (Infectious Diseases, Oncology, Hematology, Prenatal Testing, Endocrinology, and Others), End User (Physicians’ Offices, Hospitals and ICUs, Research Institutes, and Others), and Region 2025-2033
Purchase Options New Year Sale
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials